A Phase 3 interventional study of Levonorgestrel (BAY98-7196) in Contraception, sponsored by Bayer. Completed at 100 sites in 2 countries. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2021-04-08.
Sponsored by Bayer · Phase 3, Interventional, and Prevention
Purpose of the study is to investigate safety and contraceptive efficacy of an LNG-containing intravaginal ring.
Bayer is the lead sponsor of 1,643 studies on the registry; 57 are open to participants now.
Of its 209 completed or terminated interventional studies of FDA-regulated products, 129 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Vaginal ring containing 170 mg levonorgestrel
Drug: Levonorgestrel (BAY98-7196)
Levonorgestrel 40 µg/d intravaginal ring (treatment for 365 days, 28 days wearing period for each ring)
Pregnancy rate (Pearl Index)
Pearl Index = Number of pregnancies per 100 woman-years of exposure
Time frame: Up to 12 months
Cumulative failure rate
Probability of getting pregnant
Time frame: Up to 12 months
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bayer